Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease

NCT07764146 is registered in ClinicalTrials.gov with Voyager Therapeutics as lead sponsor.

NCT NCT07764146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07764146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease
Lead sponsor
Voyager Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 3, 2026
Completion date
April 28, 2029
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer s disease